Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Featured products

Featured products

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCAPI1356 Epalrestat Featured
Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy.
More description
DC70298 CDDD11-8 Featured
CDDD11-8 is a potent CDK9 inhibitor co-targeting FLT3-ITD with Ki values of 8 and 13 nM, respectively.CDDD11-8 displays excellent kinome selectivity in a panel of 369 human kinases.CDDD11-8 displays antiproliferative activity against leukemia cell lines, and particularly potent effects against MV4-11 and MOLM-13 cells, which are known to harbor the FLT3-ITD mutation and mixed lineage leukemia (MLL) fusion proteins.CDDD11-8 causes a robust tumor growth inhibition by oral administration in animal xenografts, induces tumor regression at dose of 125 mg/kg.
More description
DC46172 IL-17 modulator 3 Featured
IL-17 modulator 3 is an IL-17 modulator (US20200247785A1). IL-17 modulator 3 can be used for the research of inflammation, cancer and autoimmune diseases.
More description
DC65846 MGD molecule Featured
DC70239 BAY 2666605 Featured
BAY2666605 is a potent, small molecule PDE3A-SLFN12 complex inducer with EC50 of 7 nM.BAY2666605 triggers the formation of a complex of two proteins called SLFN12 and PDE3A. This complex drive cancer cells into cell death by a mechanism called apoptosis.
More description
DC65845 GT-919 Featured
DC65843 HC-X029 Featured
DC65842 0G416 Featured
DC70304 CFT8634 Featured
CFT-8634 (CFT8634) is a potent, selective, orally bioavailable BRD9 BiDAC degrader with DC50 of 3 nM, high selectivity over BRD4 abd BRD7.Unlike BRD9 inhibition, BRD9 degradation is efficacious in preclinical models of synovial sarcoma and CFT8634 is ongoing for the treatment of SMARCB1-perturbed cancers.
More description
DC65838 CFT8919 Featured
DC65837 MZ-001 Featured
DC65836 H5K29116 Featured
DC65835 PF-04745637 Featured
PF-04745637 is a potent and selective TRPA1 antagonist with an IC50 of 17 nM for human TRPA1.
More description
DC65833 LNK01002 Featured
DCC1048 Bms184394 Featured
Novel selective inhibitor of RARγ
More description
DC4198 Epothilone B Featured
Epothilone B is a Taxol-like microtubule-stabilizing agent with EC0.01 of 1.8 μM.
More description
DCC3263 MCC950 free acid Featured
Potent and selective inhibitor of NLRP3, reducing interleukin-1β (IL-1β) production in vivo and attenuating the severity of experimental autoimmune encephalomyelitis (EAE)
More description
DC11754 AD 2900 Featured
AD 2900 (AD2900, AD-2900) is a novel potent, broad S1P receptor antagonist with IC50 of 3.8, 3.2, 6.2, 5.9 and 0.405 uM for S1P1, 2, 3, 4 and 5 respectively.
More description
DC12534 T5910047 Featured
T5910047 (T-5910047) is a small molecule inhibitor of MyD88-dependent signaling pathways, disrupts MyD88 homodimeric formation; inhibits SEB-induced inhibition of cytokine production in PBMCs with IC50 of 2-10 uM, also inhibits SEA-induced pro-inflammatory cytokine production, shows no toxicity in primary cells up to 100 uM.
More description
DC70333 CXCR6 inhibitor 81 Featured
CXCR6 inhibitor 81 is a potent (EC50=40 nM) and selective orally bioavailable small molecule antagonist of human CXCR6 receptor; Compound 81 displays >10-fold improvement in potency in both the β-arrestin and cAMP assays (IC50 =40 and 540 nM, respectively) compared to ML339. CXCR6 inhibitor 81 inhibits migration of SK-HEP-1 hepatoma cells in a dose dependent manner. Compound 81 has promising oral DMPK data, significantly decreases tumor growth in a 30-day mouse xenograft model of HCC.
More description
DC65168 (S)-3-Cyclopropyl-5-isopropylimidazolidine-2,4-dione Featured
DC70862 UC-764865 Featured
UC-764865 (UC764865) is a small-molecule inhibitor that targeted ubiquitin-conjugating enzyme UBE2N active site.UC-764865 blocks ubiquitination of innate immune- and inflammatory-related substrates in human AML cell lines.Inhibition of UBE2N function disrupted oncogenic immune signaling by promoting cell death of leukemic HSPCs while sparing normal HSPCs in vitro.
More description
DC22472 Naltrexone Featured
A potent, competitive antagonist for μ, κ, δ, and σ-opioid receptors with Ki of 0.0825 nM, 0.509 nM, and 8.02 nM, for MOR, KOR, and DOR, respectively.
More description
DC60349 UDP-b-L-arabinopyranose Featured
DC49271 BIM-26226 Featured
BIM-26226, gastrin-releasing peptide, is a potent and selective antagonist of bombesin receptor. BIM-26226 inhibits BN- or GRP-stimulated amylase release with IC50s in the nanomolar range. BIM-26226 can be used for the research of cancer.
More description
DC46131 Acid-C3-SSPy Featured
Acid-C3-SSPy is a cleavable DBA-DM4 linker used in the synthesis of DBA-DM4, a drug-linker conjugate for ADC.
More description
DC39821 Finasteride Carboxaldehyde Featured
Finasteride Carboxaldehyde is a metabolite of Finasteride in human bile (M2 metabolite).
More description
DC65047 Morpholine, 4-[2-(2-bromo-4-nitrophenoxy)ethyl]- Featured
DC9624 Sparteine sulfate pentahydrate Featured
(-)-Sparteine sulfate pentahydrate is a class 1a antiarrhythmic agent and a sodium channel blocker.
More description
DC28998 Heparin sodium salt (MW 15kDa) Featured
Heparin sodium salt (MW 15kDa) (Sodium heparin (MW 15kDa)) is a polymer of Heparin with the molecular weight of 15kDa. Heparin sodium salt is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa.
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X